Trials / NCT02709876
Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa
Status unknown Phase 1 / Phase 2 Cell therapy
- Sponsor
- Stem Cells Arabia
- Treatment
- Stem Cell Transplantation
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Started
- 2014-04
- Main results expected
- 2020-09
- Results posted
- Not yet
- Record last updated
- 2020-03-17
What the study is testing
A single arm, single center trial to evaluate the safety and efficacy of autologous purified populations of bone-marrow derived stem cells in patients with Retinitis Pigmentosa (BM-SCs) through a 48 month follow up period.
Where it runs
Jordan (1)
- Stem Cells Arabia, Amman